Abivax (ABVX)

• Market cap: $7.06B
• 1 day: -1.05%
• 5 days: -6.69%
• 1 month: 10.34%
• 3 months: 807.1%
• 6 months: 1,295.54%
• Year to date: 1,144.31%
• 1 year: 763.9%
• 5 years: 992.89%
• 10 years: 992.89%
• Sector: Healthcare
• Industry: Biotechnology

About: Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Employees: 69